Skip to content

CJC-1295 vs CJC-1295 (no DAC) + Ipamorelin

Updated 8 sources

Key differences

  1. 1The blend uses CJC-1295 without DAC, which gives short pulses. The DAC version keeps GH up for days, with a measured half-life of 5.8 to 8.1 days.
  2. 2Some people run CJC-1295 with DAC weekly on top of the blend, or during off-weeks.

Side by side

Facts from each record, in the same words as their own pages.
CJC-1295 and CJC-1295 (no DAC) + Ipamorelin side by side
CJC-1295CJC-1295 (no DAC) + Ipamorelin
Category
  • GH axis
  • GH axis
Evidence
  • Limited human data
  • No human trials
FDA status
  • Not FDA approvedRegulatory
  • Not FDA approvedRegulatory
WADA
  • Prohibited
  • Prohibited
Half-life
  • With DAC: 5.8 to 8.1 days in healthy adults. Without DAC: about 30 minutes per guides, never measured in humans.Competitor guide
  • Ipamorelin: about 2 hours after IV dosing. CJC-1295 no DAC: about 30 minutes per guides, never measured in humans.Competitor guide
Routes
  • Subcutaneous injection
  • Subcutaneous injection
Reported doses
  • 0.4 to 2 mg (subcutaneous injection)
  • 100 to 400 mcg (subcutaneous injection)
  • 100 to 400 mcg (subcutaneous injection)
  • 100 to 500 mcg (subcutaneous injection)
Most cited frequency
  • 1 to 2 mg a week, split into 1 or 2 injections
  • Once daily, before bed
Vial sizes
  • 2 mg, 5 mgCompetitor guide
  • 10 mgCompetitor guide
Mixed vial keeps
  • Fridge, 2 to 8 °C, and avoid freeze-thaw.Competitor guide
  • Fridge, 2 to 8 °C.Competitor guide
Protocols on file
  • 9
  • 8

Doses shown are what sources report, labelled by origin. Not medical advice.

Read each in full

Sources

8 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.

Clinical study3

  1. CJC-1295 in healthy adults (Teichman 2006)PubMed · checked Oct 23, 2026
  2. Performance-enhancing peptides modulating GH-IGF1 axis (Dominikowski 2026)PMC · checked Oct 23, 2026
  3. Ipamorelin PK-PD (Gobburu 1999)PubMed · checked Oct 23, 2026

Regulatory3

  1. Certain bulk drug substances, safety risksFDA · checked Oct 23, 2026
  2. 503A bulk drug substance categories (May 14, 2026)FDA · checked Oct 23, 2026
  3. WADA Prohibited List 2026WADA · checked Oct 23, 2026

Competitor guide2

  1. CJC/IPA blend dosage guideBodyHackGuide · checked Oct 23, 2026
  2. CJC-1295 no DAC dosage guideBodyHackGuide · checked Oct 23, 2026